Insider Buying Sparks Interest: Recent discussions on X about Summit Therapeutics (SMMT) have centered on significant insider purchases by company executives, with reports of Co-CEOs buying shares worth nearly $500,000 each. This activity, noted in web updates, has led to a buzz among investors, with some seeing it as a strong signal of confidence in the company’s future. After-hours trading saw a 4% uptick following the news, fueling further conversation.
Q3 Results Stir Debate: The release of Summit Therapeutics’ third-quarter results has also drawn attention on X, with the company reporting a wider-than-expected loss per share. Posts highlight mixed reactions, as some focus on the loss while others note progress in the Ivonescimab cancer program and plans for regulatory submissions. The stock dipped after the announcement, adding to the ongoing debate about its trajectory.
Analyst Ratings and Future Potential: X chatter also reflects on recent analyst reaffirmations, with some users pointing to a 'Buy' rating and a high price target as reasons for optimism. Discussions often mention the potential for big pharma deals due to Summit’s late-stage cancer assets and clean balance sheet. This keeps the tone hopeful among certain circles despite short-term volatility.
Note: This discussion summary was generated from an AI condensation of post data.
Summit Therapeutics Insider Trading Activity
Summit Therapeutics insiders have traded $SMMT stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SMMT stock by insiders over the last 6 months:
- YU XIA purchased 533,617 shares for an estimated $9,999,982
- ROBERT W DUGGAN (Co-Chief Executive Officer) has made 3 purchases buying 365,074 shares for an estimated $6,484,739 and 0 sales.
- MAHKAM ZANGANEH (Co-Chief Executive Officer) has made 3 purchases buying 365,074 shares for an estimated $6,484,739 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Summit Therapeutics Hedge Fund Activity
We have seen 137 institutional investors add shares of Summit Therapeutics stock to their portfolio, and 117 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER BROS. ADVISORS LP added 9,298,109 shares (+38.1%) to their portfolio in Q2 2025, for an estimated $197,863,759
- VANGUARD GROUP INC removed 2,966,835 shares (-25.5%) from their portfolio in Q2 2025, for an estimated $63,134,248
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,652,656 shares (-40.5%) from their portfolio in Q2 2025, for an estimated $56,448,519
- BALYASNY ASSET MANAGEMENT L.P. removed 1,703,180 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $36,243,670
- BLACKROCK, INC. removed 1,550,889 shares (-18.5%) from their portfolio in Q2 2025, for an estimated $33,002,917
- NORGES BANK added 1,289,862 shares (+1289.9%) to their portfolio in Q2 2025, for an estimated $27,448,263
- APEIRON CAPITAL LTD added 1,200,941 shares (+inf%) to their portfolio in Q2 2025, for an estimated $25,556,024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Summit Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $SMMT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 10/22/2025
- Barclays issued a "Underweight" rating on 10/21/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/21/2025
- JMP Securities issued a "Market Outperform" rating on 10/20/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/08/2025
- Evercore ISI Group issued a "Outperform" rating on 08/12/2025
- UBS issued a "Buy" rating on 07/01/2025
To track analyst ratings and price targets for Summit Therapeutics, check out Quiver Quantitative's $SMMT forecast page.
Summit Therapeutics Price Targets
Multiple analysts have issued price targets for $SMMT recently. We have seen 12 analysts offer price targets for $SMMT in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Brad Canino from Guggenheim set a target price of $40.0 on 10/22/2025
- Etzer Darout from Barclays set a target price of $16.0 on 10/21/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $40.0 on 10/21/2025
- Reni J. Benjamin from JMP Securities set a target price of $40.0 on 10/20/2025
- Yigal Nochomovitz from Citigroup set a target price of $40.0 on 10/20/2025
- Kelsey Goodwin from Piper Sandler set a target price of $21.0 on 08/19/2025
- Cory Kasimov from Evercore ISI Group set a target price of $34.0 on 08/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
